Trial Profile

A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC Genotype

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exagamglogene autotemcel (Primary)
Indications Sickle cell anaemia
Focus Therapeutic Use
Acronyms CLIMB-161
Sponsors Vertex Pharmaceuticals

Most Recent Events

28 Feb 2024 Planned initiation date changed from 1 Jan 2024 to 1 Apr 2024.
05 Feb 2023 New trial record
10 Dec 2022 According to CRISPR Therapeutics media release, patients from this study will be asked to participate in CLIMB-131 long term follow-up trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com